此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

2018年8月7日 更新者：GlaxoSmithKline

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease

The study is designed to investigate the effects of rilapladib on biomarkers related to the Alzheimer's disease, and cognitive function.

研究概览

地位

完全的

条件

干预/治疗

详细说明

The study is in subjects with Alzheimer's disease and evidence of cerebrovascular disease (CVD) who are currently treated with an acetylcholinesterase inhibitor (AChEI) and/or memantine. The study is a randomized, double-blind, placebo controlled, parallel group, repeat dose design, in which subjects (up to 60 randomized subjects per arm) will receive oral placebo or rilapladib (250 mg), once daily for 24 weeks in addition to their stable background AD therapy consisting of an acetylcholinesterase inhibitor (AChEI) and/or memantine. Subjects will take 250mg of rilapladib or placebo once daily for a period of 24 weeks. The total duration of participation for each subject will be approximately 30 weeks comprising approximately 4 weeks screening, 24 weeks treatment and 2 weeks follow-up. From the time of randomization and throughout the treatment period subjects will attend visits after 1 week, 4 weeks and thereafter every 4 weeks until Week 24. A follow-up visit will occur approximately 2 weeks after the final dose of study medication. Cognitive assessments will be performed at the screening visit, at the randomization (baseline) visit and at weeks 12 and 24 of the treatment period. Cerebrospinal fluid (CSF) samples will be taken via lumbar puncture at baseline and Week 24 for biomarker analyses related to Alzheimer's disease. Blood samples will be collected throughout the study for pharmacokinetics and a range of biomarker analyses. A range of safety and tolerability assessments will also be performed (including vital signs, laboratory tests, eye examinations and ECGs).

研究类型

介入性

注册 (实际的)

124

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 保加利亚
      • Sofia、保加利亚、1431
        • GSK Investigational Site
      • Sofia、保加利亚、1113
        • GSK Investigational Site
  • 加拿大
    • Ontario
      • Toronto、Ontario、加拿大、M3B 2S7
        • GSK Investigational Site
    • Quebec
      • Gatineau、Quebec、加拿大、J9A 1K7
        • GSK Investigational Site
      • Sherbrooke、Quebec、加拿大、J1H 1Z1
        • GSK Investigational Site
  • 德国
    • Baden-Wuerttemberg
      • Ellwangen、Baden-Wuerttemberg、德国、73479
        • GSK Investigational Site
      • Tuebingen、Baden-Wuerttemberg、德国、72076
        • GSK Investigational Site
      • Ulm、Baden-Wuerttemberg、德国、89081
        • GSK Investigational Site
    • Bayern
      • Alzenau、Bayern、德国、63755
        • GSK Investigational Site
    • Hessen
      • Bad Homburg、Hessen、德国、61348
        • GSK Investigational Site
    • Niedersachsen
      • Achim、Niedersachsen、德国、28832
        • GSK Investigational Site
      • Hannover、Niedersachsen、德国、30559
        • GSK Investigational Site
    • Nordrhein-Westfalen
      • Bochum、Nordrhein-Westfalen、德国、44787
        • GSK Investigational Site
      • Bochum、Nordrhein-Westfalen、德国、44791
        • GSK Investigational Site
      • Bochum、Nordrhein-Westfalen、德国、44892
        • GSK Investigational Site
      • Koeln、Nordrhein-Westfalen、德国、50935
        • GSK Investigational Site
    • Schleswig-Holstein
      • Oldenburg、Schleswig-Holstein、德国、26122
        • GSK Investigational Site
  • 意大利
    • Lazio
      • Roma、Lazio、意大利、00185
        • GSK Investigational Site
    • Liguria
      • Genova、Liguria、意大利、16132
        • GSK Investigational Site
    • Lombardia
      • Brescia、Lombardia、意大利、25125
        • GSK Investigational Site
      • Milano、Lombardia、意大利、20122
        • GSK Investigational Site
    • Veneto
      • Verona、Veneto、意大利、37134
        • GSK Investigational Site
  • 挪威
      • Lørenskog、挪威、1478
        • GSK Investigational Site
  • 瑞典
      • Stockholm、瑞典、SE-141 86
        • GSK Investigational Site
  • 西班牙
      • Baracaldo/Vizcaya、西班牙、48903
        • GSK Investigational Site
      • Barcelona、西班牙、08014
        • GSK Investigational Site
      • Castellón de La Plana、西班牙、12004
        • GSK Investigational Site
      • Getafe/Madrid、西班牙、28905
        • GSK Investigational Site
      • L'Hospitalet de Llobregat、西班牙、08907
        • GSK Investigational Site
      • Madrid、西班牙、28006
        • GSK Investigational Site

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. A clinical diagnosis of possible Alzheimer's disease in accordance with the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with radiological (Magnetic Resonance Imaging [MRI] or Computed Tomography [CT]) evidence of significant cerebrovascular disease (CVD), assessed within the last 12 months
  2. Male or female between 50 and 80 years of age inclusive, at the time of signing the informed consent.
  3. Subject has a documented history of at least 6 months of ongoing Alzheimer's disease therapy (AChEIs and/or memantine) with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
  4. Mini-Mental Status Examination (MMSE) score between 20 and 26 at Screening.
  5. Clinical Dementia Rating Scale (CDR) score of 0.5 or 1.0 at Screening.
  6. A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea; or of child-bearing potential and agrees to use acceptable contraception methods
  7. Subject has provided full written informed consent prior to the performance of any protocol-specified procedure; or if the subject is unable to provide informed consent due to cognitive status, the subject will provide assent and full written informed consent will be provided by a legally acceptable representative
  8. The subject has a dedicated caregiver who is willing to supervise participation in the study
  9. In the opinion of the investigator, the subject has the ability to comply with study procedures (cognitive and other testing) and is fluent in the language used for the administration of the cognitive tests.

Exclusion Criteria:

  1. History and/or evidence of any other CNS disorder that could be interpreted as a cause of dementia: e.g. structural or developmental abnormality, epilepsy, infectious, degenerative or inflammatory/demyelinating CNS conditions such as, Parkinson's disease and frontotemporal dementia
  2. History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study; major depressive disorder (according to DSM-IV) in the past year; current active depression requiring initiation of treatment (or is believed to account for substantial degree of cognitive impairment)
  3. Evidence of the following disorders: current vitamin B12 deficiency, positive syphilis serology (unless neurosyphilis was ruled out) or active thyroid dysfunction (particularly suggestive of hypothyroidism), including abnormally high or low serum levels of thyroid stimulating hormone (TSH), where this is thought to be the cause of, or to contribute to the severity of the subject's dementia.
  4. History of alcohol or other substance abuse, according to the DSM-IV criteria, or recent or remote history of the same if that could be a contributing factor to dementia.
  5. History of intra cerebral haemorrhage due to any of the following causes: cerebral amyloid angiopathy, uncontrolled hypertension, cerebral arteriovenous malformation, coagulopathy, CNS vasculitis or any other condition that the investigator and/or medical monitor considers as a relevant risk factor for intracerebral haemorrhage

  6. Recent (i.e.,<6 months from Screening Visit) cardiovascular event defined as:

    1. ST-elevation MI or non-ST-elevation MI, confirmed by cardiac enzyme elevation and ECG changes
    2. coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft )
    3. stroke of any etiology
    4. resuscitated sudden death
    5. prior carotid surgery or stenting procedure
  7. Poorly controlled hypertension despite lifestyle modifications and pharmacotherapy (either systolic blood pressure >160mmHg or diastolic blood pressure >110mmHg)
  8. QTcB interval >450 msec; or QTcB > 480 msec in subjects with bundle branch block based on ECG assessment at the Screening visit.
  9. HbA1c >12.0 at Screening, or uncontrolled diabetes in the opinion of the investigator.
  10. History of glaucoma or any other findings in the baseline eye exam that, in the opinion of the investigator, would exclude the subject from participation in the study.
  11. History of adult asthma (or reactive airway disease) manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s).
  12. Previous history of anaphylaxis, severe allergic reaction or history of hypersensitivity to any of the components of the formulation.
  13. Significant abnormalities on clinical chemistry, haematology or urinalysis at Screening, including clinically significant anaemia.
  14. History of chronic viral hepatitis (including presence of B surface antigen or hepatitis C antibody), or other chronic hepatic disorders.

  15. Abnormal Screening blood tests exceeding any of the limits defined below:

    1. Alanine transaminase (ALT) or aspartate transaminase (AST) >1.5 x the upper limit of normal (ULN)
    2. Alkaline phosphatase (AP) and bilirubin >1.5X ULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
    3. Calculated creatinine clearance < 30 ml/min (per Cockcroft & Gault) at Screening
  16. Other clinically significant abnormality on physical (including neurological), laboratory or ECG examination that could be detrimental to the subject in the opinion of the Investigator or could compromise the integrity of the study.
  17. Planned major surgery within the study period.
  18. Use of systemic steroids or other immunosuppressants within the last 30 days prior to screening.
  19. Current treatment with barbiturates, MAO inhibitors, butyrophenones, phenothiazines and other "conventional" antipsychotic within 30 days or 5 half-lives prior to Screening, whichever is longer.
  20. Treatment with antidepressants, (other than MAO inhibitors), thyroid hormones, atypical antipsychotics (e.g. risperidone), benzodiazepines and other sedatives / hypnotics unless prescribed at a stable dose for at least 2 months prior to Screening. Note: Benzodiazepines or other sedatives/hypnotics (including antihistamines) with half-life less than 6 hours can be taken on a prn (as needed) basis but must not be taken within 5 half lives prior to cognitive testing.
  21. Current treatment with known potent inhibitors of CYP3A4 (e.g. ketoconazole, rifampin, modafinil).
  22. Current treatment with known potent Pgp inhibitors (itraconazole, ketoconazole, cyclosporin, loperamide, diltiazem, verapamil, spironolactone, quinidine, bepridil, quinine, carvedilol)
  23. Cognitive tasks prescribed for cognitive rehabilitation and performed under medical supervision in the 6 months prior to screening and/or during study
  24. Investigational medications or devices including symptomatic AD treatment during the 60 days prior to the Screening visit, or within 5 half-lives of use of the investigational drug prior to the Screening Visit, whichever is longer.

  25. Participation in another investigational drug (with the exception of anti-amyloid monoclonal antibodies [mAbs]) or device study where subject was treated chronically (i.e. > 1 single dose) with a study agent intended to impact AD progression during the 12 months prior to the Screening visit.

    1. Subjects who participated in an investigational drug study that involved chronic dosing with a monoclonal antibody at any time in the past are excluded from this study, unless it is known that they received placebo during the previous study.
    2. Subjects who participated in previous single-dose studies of anti-amyloid mAbs will be permitted provided the subject's dose of the mAb is at least 5 half-lives removed; the subjects did not experience any moderate adverse events classified as possibly drug-related or any serious adverse event during that study; the subject did not drop out of the previous study (i.e. completed all safety assessments)
  26. Subjects, who in the investigator's judgement, pose a significant suicide risk (e.g. history of suicidal behaviour in the last 6 months and/or any suicidal ideation of type 4 or 5 on the C-SSRS in the last 2 months).
  27. Subject or caregiver is an immediate family member or employee of the participating Investigator, any of the participating site staff or GSK staff.

  28. Any contraindication to lumbar puncture or insertion of CSF catheter, including but not limited to

    1. Thrombocytopenia or other coagulation disorders (including subjects receiving coumarin-derived anti-coagulants or low-molecular-weight heparin).
    2. The presence of cutaneous or soft tissue infection overlying or adjacent to the site of lumbar puncture.
    3. Previous spinal surgery that could complicate access to the subarachnoid space.
    4. Suspicion of increased intracranial pressure due to a cerebral mass.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：三倍

武器和干预

参与者组/臂
干预/治疗
实验性的：250mg rilapladib
Experimental drug
药品：250mg rilapladib
Experimental Drug
安慰剂比较：安慰剂
安慰剂比较器
药品：安慰剂
安慰剂对照

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24
大体时间：Baseline (Day 0) and Week 24
CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42 and Abeta40 are summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in CSF Abeta42/ Abeta40 Ratio at Week 24
大体时间：Baseline (Day 0) and Week 24
CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42/Abeta40 ratio is summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24
大体时间：Baseline (Day 0) and Week 24
CSF tau and P-tau were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF tau and P-tau was summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in the Computerized Test Battery for Cognition (CogState) Battery Working Memory/Executive Function (WM/EF) Composite Score at Week 24
大体时间：Baseline (Day 0) and Week 24
The WM/EF composite score was comprised of 5 functional tests including 1) Controlled oral word association which measured language fluency, planning and working memory, 2) Category naming: It measures semantic fluency, planning and working memory, 3) One-back: This is a measure of working memory. 4) Trail B: This is a measure of motor speed, visual scanning, and visual-motor integration. This test required attention and cognitive flexibility. 5) Go No-Go task: This test evaluate accuracy and reaction time for each response. The composite score calculated by standardizing the total score: sum of all responses obtained from these 5 functional test by using the formula (Total score of ITT population at baseline - Total score at Week 24) /standard deviation of mean total mean score at baseline. The observed composite score ranged from minimum -1.474 and maximum 1.596. Lower score means better cognitive status. Change from Baseline was calculated as post-dose visit minus Baseline value.
Baseline (Day 0) and Week 24

次要结果测量

结果测量
措施说明
大体时间
Change From Baseline (Day 0) in CSF Albumin Quotients at Week 24
大体时间：Baseline (Day 0) and Week 24
CSF albumin quotient was assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in albumin quotient is summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24
大体时间：Baseline (Day 0) and Week 24
Plasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in plasma Abeta42 and Abeta40 are summarized. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in Plasma Levels of Abeta42/Abeta40 Ratio at Week 24
大体时间：Baseline (Day 0) and Week 24
Plasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in plasma Abeta42/Abeta40 ratio is summarized. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Baseline (Day 0) and Week 24
Percentage Inhibition in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity at Week 24
大体时间：Baseline (Day 0) and Week 24
Plasma Lp-PLA2 was assessed at Baseline visit (Day 0) and Week 24 (Day 168). Percentage inhibition in plasma Lp-PLA2 activity ratio is summarized. Percentage inhibition was calculated by dividing change from Baseline in plasma LpPLA2 by Baseline LpPLA2 multiplied by -100. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value.
Baseline (Day 0) and Week 24
Change From Baseline (Day 0) in CogState Battery Overall Composite Score
大体时间：Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
CogState battery overall composite score comprised of 8 functional tests 1) Controlled oral word association test measured language fluency, planning and working memory. 2) Category naming test measured semantic fluency, planning and working memory. 3) One-back test measured working memory. 4) Trail B test measured motor speed, visual scanning and visual-motor integration, required attention and cognitive flexibility. 5) Go No-Go task evaluated accuracy and reaction time for each response. 6) International shopping list immediate and delayed recall tests measured episodic memory. 7) Identification task test assessed visual attention. 8) Trail A test measured psychomotor speed and attention. Composite score= total score (sum of all responses from 8 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline. Score ranged: -1.070 to 0.907. Lower score indicated the better cognitive status. Change from Baseline= post-dose visit minus Baseline value
Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
Change From Baseline (Day 0) in CogState Battery Attention Composite Score
大体时间：Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
CogState battery attention composite score comprised of 2 functional tests including 1) Identification task test assessed visual attention and 2) Trail A test measured psychomotor speed and attention. Composite score calculated by standardizing the total score (sum of all responses from 2 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline. The observed composite score ranged from minimum -1.756 and maximum 1.330. Higher score indicated the better attention. Baseline value was defined as the latest Day 0 value and Change from Baseline was calculated as post-dose visit minus Baseline value
Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

GlaxoSmithKline

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2011年10月1日

初级完成 (实际的)

2013年2月4日

研究完成 (实际的)

2013年2月18日

研究注册日期

首次提交

2011年9月1日

首先提交符合 QC 标准的

2011年9月1日

首次发布 (估计)

2011年9月5日

研究记录更新

最后更新发布 (实际的)

2018年9月24日

上次提交的符合 QC 标准的更新

2018年8月7日

最后验证

2017年7月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • 114458

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

是的

IPD 计划说明

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

研究数据/文件

  1. 数据集规范
    信息标识符：114458
    信息评论：For additional information about this study please refer to the GSK Clinical Study Register
  2. 个人参与者数据集
    信息标识符：114458
    信息评论：For additional information about this study please refer to the GSK Clinical Study Register
  3. 知情同意书
    信息标识符：114458
    信息评论：For additional information about this study please refer to the GSK Clinical Study Register
  4. 统计分析计划
    信息标识符：114458
    信息评论：For additional information about this study please refer to the GSK Clinical Study Register
  5. 研究协议
    信息标识符：114458
    信息评论：For additional information about this study please refer to the GSK Clinical Study Register
  6. 带注释的病例报告表
    信息标识符：114458
    信息评论：For additional information about this study please refer to the GSK Clinical Study Register
  7. 临床研究报告
    信息标识符：114458
    信息评论：For additional information about this study please refer to the GSK Clinical Study Register

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅